Saturday 17 October 2026
Export SINT’s income statement to Excel — free account
SINTX TECHNOLOGIES, INC.
SINT Healthcare Medical Devices
SINTX TECHNOLOGIES, INC.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 64.7% from fiscal 2024. In the quarter to June 2026, revenue grew 199.3%, EPS grew 17.6%, free cash flow fell 38.6% and total debt fell 6.42%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.74
0.03
−1.69%
Follow SINT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 4,320,000.00 | 1,734,000.00 | 96,000.00 | 25,000.00 | 5,600.00 | 11,700.00 | 1,292.00 | 67.00 | 2.01 | 1.71 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 26,064,000.00 | 5,320,800.00 | 2,472,000.00 | 209,400.00 | 66,000.00 | 68,800.00 | 14,400.00 | 2,428.00 | 85.20 | 7.36 | |||||
| People | |||||||||||||||
| People | Employees | 35 | 33 | 19 | 28 | 32 | 36 | 41 | 43 | 20 | 32 | ||||
| Revenue/emp, $m | 0.44 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.04 | 0.06 | 0.14 | 0.03 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | 15 | — | 0 | 1 | 1 | 1 | 2 | 3 | 3 | 1 | ||||
| Gross margin, % | 75.19 | 0.00 | 41.05 | 20.03 | 20.03 | 25.91 | 83.02 | 70.16 | 71.91 | 45.28 | |||||
| EBT | (15) | (6) | (10) | (5) | (7) | (9) | (12) | (8) | (11) | (10) | |||||
| EBT margin, % | (96.96) | 0.00 | (10,198.95) | (696.23) | (1,183.33) | (1,536.14) | (771.24) | (314.39) | (381.85) | (1,018.07) | |||||
| Net income | (15) | (6) | (10) | (5) | (7) | (9) | (12) | (8) | (11) | (10) | |||||
| Depreciation | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 9.86 | 0.00 | 0.00 | 6,890.00 | 742.50 | 505.00 | 1,040.67 | 140.48 | 3.89 | 0.37 | ||||
| Earnings | (8,868,412.00) | (1,879,880.00) | (1,237,237.00) | (61,600.00) | (7,020.60) | (7,105.40) | (7,502.80) | (444.00) | (14.87) | (6.16) | |||||
| Cash flow | (4.64) | (1.57) | 0.00 | (64,350.00) | (11,390.00) | (8,439.17) | (6,842.00) | (754.81) | (11.66) | (3.09) | |||||
| Capex | (0.40) | 0.00 | 0.00 | (1,470.00) | (450.00) | (3,000.00) | (936.00) | (26.79) | (0.90) | 0.06 | |||||
| Free cash flow | (5.04) | (1.57) | 0.00 | (65,820.00) | (11,840.00) | (11,439.17) | (7,778.00) | (781.60) | (12.56) | (3.03) | |||||
| Book value | 7.28 | 1.83 | 0.00 | 52,020.00 | 32,255.00 | 14,329.17 | 3,802.67 | 469.09 | 5.25 | 1.06 | |||||
| Shares, m | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | 472,387.34 | — | 0.00 | 4.33 | 42.29 | 25.43 | 1.85 | 0.55 | 0.90 | 10.52 | |||||
| P/B | 640,193.11 | — | 0.00 | 0.57 | 0.97 | 0.90 | 0.50 | 0.17 | 0.67 | 3.66 | |||||
| EV/Sales | 472,387.35 | — | (0.41) | 1.76 | 0.28 | 5.84 | (1.82) | (0.70) | (0.33) | 6.47 | |||||
| EV/FCF | (923,663.76) | — | 0.59 | (0.19) | (0.02) | (0.26) | 0.24 | 0.13 | 0.10 | (0.78) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (7) | (5) | (9) | (6) | (9) | (10) | (10) | (14) | (9) | (9) | ||||
| Capex | (1) | 0 | 0 | 0 | 0 | (4) | (1) | (1) | (1) | 0 | |||||
| Free cash flow | (8) | (5) | (9) | (7) | (9) | (14) | (12) | (15) | (9) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 2 | (5) | 5 | 2 | 25 | 12 | (1) | 3 | 3 | 2 | ||||
| Total debt | 7 | 1 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | |||||
| Net debt | 0 | 0 | (5) | (2) | (25) | (12) | (6) | (3) | (4) | (4) | |||||
| Shareholders’ equity | 11 | 5 | 8 | 5 | 26 | 17 | 6 | 9 | 4 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (67.74) | (45.62) | (172.44) | (72.60) | (83.82) | (35.61) | (87.68) | (53.21) | (88.98) | (180.59) | ||||
| ROIC | (63.62) | (84.93) | (262.66) | (120.05) | (626.03) | (124.55) | 0.00 | (152.41) | (2,676.64) | 0.00 | |||||
| ROE | (165.24) | (111.88) | (325.87) | (110.29) | (107.04) | (43.30) | (144.02) | (114.47) | (174.07) | (500.75) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jun 2026
Charts ten years each
SINTX TECHNOLOGIES, INC. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LFWD Lifeward Ltd. | $17.2M | — (loss-making) | — (loss-making) | +15.71% (above 0%: growing) | n/m | −52.77% (below 0%: shrinking) | 40.90% | (62.69%) | Compare |
| ALUR Allurion Technologies, Inc. | $16.7M | — (loss-making) | — (loss-making) | −47.19% (below 0%: shrinking) | n/m | +65.98% (above 0%: growing) | 41.70% | (126.60%) | Compare |
| HSCS HeartSciences Inc. | $15.4M | — (loss-making) | — (loss-making) | −46.15% (below 0%: shrinking) | n/m | +18.18% (above 0%: growing) | 61.90% | (139,957.14%) | Compare |
| IRIX IRIDEX Corporation | $14.5M | — (loss-making) | — (loss-making) | −7.41% (below 0%: shrinking) | n/m | +130.24% (above 0%: growing) | 34.19% | (8.19%) | Compare |
| RBOT Vicarious Surgical Inc. | $14.3M | — (loss-making) | — | — | n/m | +47.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SINT SINTX TECHNOLOGIES, INC. | $13.4M | — (loss-making) | — (loss-making) | +199.34% (above 0%: growing) | n/m | −38.60% (below 0%: shrinking) | 61.50% | (638.94%) | |
| PETV PetVivo Holdings, Inc. | $12.9M | — (loss-making) | — (loss-making) | +13.48% (above 0%: growing) | n/m | +40.13% (above 0%: growing) | 66.14% | (476.54%) | Compare |
| BTCY Biotricity Inc. | $10.9M | — (loss-making) | — (loss-making) | +10.40% (above 0%: growing) | n/m | +235.83% (above 0%: growing) | 82.55% | 3.70% | Compare |
| CTSO Cytosorbents Corporation | $9.7M | — (loss-making) | — (loss-making) | +0.17% (above 0%: growing) | n/m | +64.90% (above 0%: growing) | 73.18% | (27.39%) | Compare |
| Median of peers | $14.4M | — | — | +0.17% | — | +56.12% | 51.80% | (45.04%) |
SINTX TECHNOLOGIES, INC. (SINT) key facts
- Concern: SINTX TECHNOLOGIES, INC.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 million, down 64.7% from fiscal 2024.
- SINTX TECHNOLOGIES, INC. (SINT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SINT traded at $1.74, a market capitalization of $13.4 million.
- Return on equity was −500.8% and debt-to-equity 0.02.
- Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −45.42 (distress zone) for fiscal 2025.